O	0	10	Randomized
O	10	11	,
O	12	22	controlled
O	23	28	trial
O	29	31	of
B-intervention	32	36	yoga
O	37	39	in
O	40	45	women
O	46	50	with
O	51	57	breast
O	58	64	cancer
O	65	75	undergoing
O	76	88	radiotherapy
O	88	89	.

O	90	98	Previous
O	99	107	research
O	108	121	incorporating
O	122	126	yoga
O	127	128	(
O	128	130	YG
O	130	131	)
O	132	136	into
O	137	149	radiotherapy
O	150	151	(
O	151	154	XRT
O	154	155	)
O	156	159	for
O	160	165	women
O	166	170	with
O	171	177	breast
O	178	184	cancer
O	185	190	finds
O	191	199	improved
O	200	207	quality
O	208	210	of
O	211	215	life
O	216	217	(
O	217	220	QOL
O	220	221	)
O	221	222	.

O	223	230	However
O	230	231	,
O	232	244	shortcomings
O	245	247	in
O	248	252	this
O	253	261	research
O	262	267	limit
O	268	271	the
O	272	280	findings
O	280	281	.

B-eligibility	282	290	Patients
I-eligibility	291	295	with
I-eligibility	296	302	stages
I-eligibility	303	304	0
I-eligibility	305	307	to
I-eligibility	308	311	III
I-eligibility	312	318	breast
I-eligibility	319	325	cancer
O	326	330	were
O	331	340	recruited
O	341	347	before
O	348	356	starting
O	357	360	XRT
O	361	364	and
O	365	369	were
O	370	378	randomly
O	379	387	assigned
O	388	390	to
O	391	393	YG
O	394	395	(
O	395	396	n
O	397	398	=
B-intervention-participants	399	401	53
O	401	402	)
O	403	405	or
B-control	406	416	stretching
O	417	418	(
O	418	420	ST
O	420	421	;
O	422	423	n
O	424	425	=
B-control-participants	426	428	56
O	428	429	)
O	430	435	three
O	436	441	times
O	442	443	a
O	444	448	week
O	449	452	for
O	453	454	6
O	455	460	weeks
O	461	467	during
O	468	471	XRT
O	472	474	or
B-control	475	483	waitlist
O	484	485	(
O	485	487	WL
O	487	488	;
O	489	490	n
O	491	492	=
B-control-participants	493	495	54
O	495	496	)
O	497	504	control
O	504	505	.

O	506	510	Self
O	510	511	-
O	511	517	report
O	518	526	measures
O	527	529	of
B-outcome-Measure	530	533	QOL
O	534	535	(
O	535	542	Medical
O	543	551	Outcomes
O	552	557	Study
O	558	560	36
O	560	561	-
O	561	565	item
O	566	571	short
O	571	572	-
O	572	576	form
O	577	583	survey
O	583	584	;
O	585	592	primary
O	593	601	outcomes
O	601	602	)
O	602	603	,
B-outcome-Measure	604	611	fatigue
O	611	612	,
B-outcome-Measure	613	623	depression
O	623	624	,
O	625	628	and
B-outcome-Measure	629	634	sleep
I-outcome-Measure	635	642	quality
O	642	643	,
O	644	647	and
O	648	652	five
O	653	659	saliva
O	660	667	samples
O	668	671	per
O	672	675	day
O	676	679	for
O	680	681	3
O	682	693	consecutive
O	694	698	days
O	699	703	were
O	704	713	collected
O	714	716	at
O	717	725	baseline
O	725	726	,
O	727	730	end
O	731	733	of
O	734	743	treatment
O	743	744	,
O	745	748	and
O	749	750	1
O	750	751	,
O	752	753	3
O	753	754	,
O	755	758	and
O	759	760	6
O	761	767	months
O	768	773	later
O	773	774	.

O	775	778	The
O	779	781	YG
O	782	787	group
O	788	791	had
O	792	805	significantly
O	806	813	greater
O	814	823	increases
O	824	826	in
B-outcome	827	835	physical
I-outcome	836	845	component
I-outcome	846	851	scale
I-outcome	852	858	scores
O	859	867	compared
O	868	872	with
O	873	876	the
O	877	879	WL
O	880	885	group
O	886	888	at
O	889	890	1
O	891	894	and
O	895	896	3
O	897	903	months
O	904	909	after
O	910	913	XRT
O	914	915	(
O	915	916	P
O	917	918	=
O	919	920	.
O	920	922	01
O	923	926	and
O	927	928	P
O	929	930	=
O	931	932	.
O	932	934	01
O	934	935	)
O	935	936	.

O	937	939	At
O	940	941	1
O	941	942	,
O	943	944	3
O	944	945	,
O	946	949	and
O	950	951	6
O	952	958	months
O	958	959	,
O	960	963	the
O	964	966	YG
O	967	972	group
O	973	976	had
O	977	984	greater
O	985	994	increases
O	995	997	in
B-outcome	998	1006	physical
I-outcome	1007	1018	functioning
O	1019	1027	compared
O	1028	1032	with
O	1033	1037	both
O	1038	1040	ST
O	1041	1044	and
O	1045	1047	WL
O	1048	1054	groups
O	1055	1056	(
O	1056	1057	P
O	1058	1059	<
O	1060	1061	.
O	1061	1063	05
O	1063	1064	)
O	1064	1065	,
O	1066	1070	with
O	1071	1073	ST
O	1074	1077	and
O	1078	1080	WL
O	1081	1092	differences
O	1093	1095	at
O	1096	1100	only
O	1101	1102	3
O	1103	1109	months
O	1110	1111	(
O	1111	1112	P
O	1113	1114	<
O	1115	1116	.
O	1116	1118	02
O	1118	1119	)
O	1119	1120	.

O	1121	1124	The
O	1125	1130	group
O	1131	1142	differences
O	1143	1147	were
O	1148	1155	similar
O	1156	1159	for
O	1160	1167	general
O	1168	1174	health
O	1175	1182	reports
O	1182	1183	.

O	1184	1186	By
O	1187	1190	the
O	1191	1194	end
O	1195	1197	of
O	1198	1201	XRT
O	1201	1202	,
O	1203	1206	the
O	1207	1209	YG
O	1210	1213	and
O	1214	1216	ST
O	1217	1223	groups
O	1224	1228	also
O	1229	1232	had
O	1233	1234	a
O	1235	1244	reduction
O	1245	1247	in
B-outcome	1248	1255	fatigue
O	1256	1257	(
O	1257	1258	P
O	1259	1260	<
O	1261	1262	.
O	1262	1264	05
O	1264	1265	)
O	1265	1266	.

O	1267	1272	There
O	1273	1277	were
O	1278	1280	no
O	1281	1286	group
O	1287	1298	differences
O	1299	1302	for
B-outcome	1303	1309	mental
I-outcome	1310	1316	health
I-outcome	1317	1320	and
I-outcome	1321	1326	sleep
I-outcome	1327	1334	quality
O	1334	1335	.

B-outcome	1336	1344	Cortisol
I-outcome	1345	1350	slope
O	1351	1354	was
O	1355	1363	steepest
O	1364	1367	for
O	1368	1371	the
O	1372	1374	YG
O	1375	1380	group
O	1381	1389	compared
O	1390	1394	with
O	1395	1398	the
O	1399	1401	ST
O	1402	1405	and
O	1406	1408	WL
O	1409	1415	groups
O	1416	1418	at
O	1419	1422	the
O	1423	1426	end
O	1427	1428	(
O	1428	1429	P
O	1430	1431	=
O	1432	1433	.
O	1433	1436	023
O	1437	1440	and
O	1441	1442	P
O	1443	1444	=
O	1445	1446	.
O	1446	1449	008
O	1449	1450	)
O	1451	1454	and
O	1455	1456	1
O	1457	1462	month
O	1463	1468	after
O	1469	1472	XRT
O	1473	1474	(
O	1474	1475	P
O	1476	1477	=
O	1478	1479	.
O	1479	1481	05
O	1482	1485	and
O	1486	1487	P
O	1488	1489	=
O	1490	1491	.
O	1491	1493	04
O	1493	1494	)
O	1494	1495	.

O	1496	1498	YG
O	1499	1507	improved
O	1508	1511	QOL
O	1512	1515	and
O	1516	1529	physiological
O	1530	1537	changes
O	1538	1548	associated
O	1549	1553	with
O	1554	1557	XRT
O	1558	1564	beyond
O	1565	1568	the
O	1569	1577	benefits
O	1578	1580	of
O	1581	1587	simple
O	1588	1590	ST
O	1591	1600	exercises
O	1600	1601	,
O	1602	1605	and
O	1606	1611	these
O	1612	1620	benefits
O	1621	1627	appear
O	1628	1630	to
O	1631	1635	have
O	1636	1640	long
O	1640	1641	-
O	1641	1645	term
O	1646	1656	durability
O	1656	1657	.
